CoChat

DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!

Open access
DeVries, J. Hans, Rosenstock, Julio · 2017 · Diabetes Care
Cited by 39

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Following the U.S. Food and Drug Administration (FDA) Guidance issued in 2008 to demonstrate cardiovascular safety for the purpose of regulatory approval of new glucose-lowering agents for type 2 diabetes management, the number of placebo-controlled randomized clinical trials has increased exponentially. As previously proposed by members of the Diabetes Care editorial committee (1), these regulatory-required large cardiovascular outcome trials (CVOTs) can provide unique opportunities to learn more about the overall safety and potential off-target effects of these new drugs beyond their cardiovascular safety. Carefully conducted pooled analyses of patient-level data emanating from these CVOTs can better estimate potential adverse events that may occur infrequently or perhaps may only be seen as tenuous inconclusive signals in smaller, shorter duration, randomized controlled phase 3 trials or may emerge once the new agents are widely prescribed in clinical practice. Indeed, one such adverse event is acute pancreatitis related to incretin-based therapies consistently noted as numerical imbalances occurring in many randomized clinical trials (2). Acute pancreatitis has been a safety issue of major controversy with conflicting reports from observational retrospective studies often based on administrative insurance and prescription claim data and/or clinical practice registries. So far, reliable assessments of the relationship between pancreatitis and dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 receptor agonists based on these observational reports have been hampered by the inherent methodological shortcomings with limitations such as confounding by indication, missing data, lag-time biases, unknown residual confounding, etc. (3). Even rigorously conducted epidemiological analyses adjusting for multiple confounders cannot provide definitive answers (4). The FDA MedWatch reporting system is another unreliable source with incomplete clinical information often influenced by the media and difficult to interpret without data on the denominator. Large-scale CVOTs have now been reported for three DPP-4 inhibitors: saxagliptin, alogliptin, and sitagliptin (5–7). There were …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dci16-0035

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
DeVries, J. H., & Rosenstock, J.
Venue
Diabetes Care
Published
2017-01-11
Volume
40
Issue
2
Pages
161-163
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2571987386
Cited by
39
References
4
FWCI
3.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.